Abstract Library

#4207 START-NET: Systemic Targeted Adaptive RadioTherapy of NeuroEndocrine Tumors – An open-label, multi-center, randomised phase III trial comparing safety and efficacy of personalised vs non-personalised radionuclide therapy with 177Lu-DOTATOC

Introduction: Peptide receptor radionuclide therapy (PRRT) with fixed activity dosing is an established treatment for advanced neuroendocrine tumors (NETs). Emerging data suggest that patients may benefit from a personalized treatment approach. Aggressive NET is believed to benefit from more intensive treatment, one example being FDG-PET positive tumors have shown benefit from combining PPRT with chemotherapy. Dosimetry is another means of achieving personalisation and can be used to increase the tumor radiation doses without surpassing the toxicity limits of organs at risk.

Conference:

Presenting Author: Asp P

Authors: Asp P, Sjögreen-Gleisner K, Fröss-Baron K, Sandström M, Hallqvist A,

Keywords: NET, PRRT, dosimetry, PET, 177Lu-DOTATOC, capecitabine,

#4148 S-1/temozolomide versus S-1/temozolomide plus thalidomide in advanced pancreatic and non-pancreatic neuroendocrine tumors (STEM): A randomised, open-label, multicentre phase 2 trial

Introduction: There are currently limited systemic treatment options for patients with advanced neuroendocrine tumors (NETS) and the efficacy of existing treatments is sub-optimal.

Conference:

Presenting Author:

Authors: Chi Y, Song L, Liu W, Zhou Y, Miao Y,

Keywords: S-1, temozolomide, thalidomide, neuroendocrine tumor,

#4114 Delays in the dosing administration of PRRT in advanced neuroendocrine tumors – Is there an adverse impact?

Introduction: Peptide receptor radionuclide therapy (PRRT) has emerged as a major therapeutic component in the overall management of advanced neuroendocrine tumors (NETs). In Greece, the treatment has been performed for several years, however because of reimbursement issues, especially during the financial crisis in Greece, there is usually a delay between the administered doses beyond the recommended 6-8 weeks interval.

Conference:

Presenting Author:

Authors: Georgakopoulos A, Tsoli M, Koumarianou A, Papadopoulou N, Panagaki M,

Keywords: PRRT, Progression-free survival, overall survival,

#4113 Establishment of a rat model of diarrhea induced by Surufatinib

Introduction: Surufatinib is a novel oral small-molecule TKI for the treatment of advanced neuroendocrine tumors. However, diarrhea is a common adverse event of surufatinib which can affects patients’ quality of life and clinical efficacy. Currently, there are no available animal models to study the cause and treatmen of surufatinib-related diarrhea.

Conference:

Presenting Author: Hu S

Authors: Hu S, Guo Y, Chen Y, Cheng Z, Deng C,

Keywords: Surufatinib, diarrhea, model, rat,

#4054 Predictive factors of persistent thrombocytopenia after 177Lu-DOTATATE in patients with neuroendocrine tumors

Introduction: Peptide Receptor Radionuclide Therapy (PRRT) is an effective and well tolerated treatment for advanced Neuroendocrine Tumors (NET). However, some Persistent Thrombocytopenia (PT) are described and may compromise further therapies and outcome.

Conference:

Presenting Author:

Authors: Oziel-Taieb S, Ferrara R, Charrier N, Maniry J, Reichert T,

Keywords: Neuroendocrine Tumor, PRRT, LuDOTATATE, Thrombocytopenia, Bone metastases, spleen,